Progress of Research on Programmed Death-1/Programmed Death Ligand-1 Inhibitors for HIV/AIDS with Cancer
Immunotherapy has become a common means of cancer treatment. In immunotherapy, PD-1/PD-L1 inhibitors have significant efficacy. Cancer and various opportunistic infections are common complications in patients with AIDS. Owing to the special immune situation of these patients, AIDS is regarded as an exclusion standard in most clinical trials for cancer immunotherapy, conferring immunotherapy difficulty in treating patients with AIDS. The popularity of effective antiretroviral drugs has prolonged the lifetime of people with AIDS. Therefore, exploiting the opportunity of using immunotherapy in AIDS with cancer is urgent..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:50 |
|---|---|
| Enthalten in: |
Zhongliu Fangzhi Yanjiu - 50(2023), 9, Seite 924-928 |
| Sprache: |
Chinesisch |
|---|
| Beteiligte Personen: |
DENG Changgang [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
Aids |
|---|
| doi: |
10.3971/j.issn.1000-8578.2023.23.0102 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ096673273 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ096673273 | ||
| 003 | DE-627 | ||
| 005 | 20240413154946.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240413s2023 xx |||||o 00| ||chi c | ||
| 024 | 7 | |a 10.3971/j.issn.1000-8578.2023.23.0102 |2 doi | |
| 035 | |a (DE-627)DOAJ096673273 | ||
| 035 | |a (DE-599)DOAJd1cf928eb9824172a20edf2de93ec2be | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a chi | ||
| 050 | 0 | |a RC254-282 | |
| 100 | 0 | |a DENG Changgang |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Progress of Research on Programmed Death-1/Programmed Death Ligand-1 Inhibitors for HIV/AIDS with Cancer |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Immunotherapy has become a common means of cancer treatment. In immunotherapy, PD-1/PD-L1 inhibitors have significant efficacy. Cancer and various opportunistic infections are common complications in patients with AIDS. Owing to the special immune situation of these patients, AIDS is regarded as an exclusion standard in most clinical trials for cancer immunotherapy, conferring immunotherapy difficulty in treating patients with AIDS. The popularity of effective antiretroviral drugs has prolonged the lifetime of people with AIDS. Therefore, exploiting the opportunity of using immunotherapy in AIDS with cancer is urgent. | ||
| 650 | 4 | |a pd-1/pd-l1 inhibitor | |
| 650 | 4 | |a aids | |
| 650 | 4 | |a hiv | |
| 650 | 4 | |a cancer | |
| 653 | 0 | |a Neoplasms. Tumors. Oncology. Including cancer and carcinogens | |
| 700 | 0 | |a ZHANG Wei |e verfasserin |4 aut | |
| 700 | 0 | |a SUN Yanyu |e verfasserin |4 aut | |
| 700 | 0 | |a LI Qisui |e verfasserin |4 aut | |
| 700 | 0 | |a HUANG Wei |e verfasserin |4 aut | |
| 700 | 0 | |a YUAN Jing |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Zhongliu Fangzhi Yanjiu |d Magazine House of Cancer Research on Prevention and Treatment, 2019 |g 50(2023), 9, Seite 924-928 |w (DE-627)DOAJ000006629 |x 10008578 |7 nnns |
| 773 | 1 | 8 | |g volume:50 |g year:2023 |g number:9 |g pages:924-928 |
| 856 | 4 | 0 | |u https://doi.org/10.3971/j.issn.1000-8578.2023.23.0102 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/d1cf928eb9824172a20edf2de93ec2be |z kostenfrei |
| 856 | 4 | 0 | |u http://www.zlfzyj.com/EN/10.3971/j.issn.1000-8578.2023.23.0102 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1000-8578 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 50 |j 2023 |e 9 |h 924-928 | ||